Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: hI-con1; hIcon1; human Immuno-conjugate 1; ICON-1; Immuno-conjugate-1

Latest Information Update: 11 Apr 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Yale University
  • Developer Iconic Therapeutics; Yale University
  • Class Antineoplastics; Eye disorder therapies; Immunoconjugates; Immunoproteins; Recombinant fusion proteins
  • Mechanism of Action Angiogenesis inhibitors; Apoptosis stimulants; Immunostimulants; Natural killer cell stimulants; Thromboplastin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Wet age-related macular degeneration
  • Phase I Uveal melanoma
  • Research Solid tumours
  • No development reported Cancer

Most Recent Events

  • 26 Mar 2018 Phase-II clinical trials in Wet age-related macular degeneration (Combination therapy, In the elderly, In adults) in USA (Intravitreous) (NCT03452527)
  • 02 Mar 2018 Iconic Therapeutics plans an open label phase II trial for Wet age-related macular degeneration (Maintenance or Combination therapy, In the elderly, In adults) in USA (Intravitreous) (NCT03452527)
  • 01 Sep 2017 Iconic Therapeutics completes a phase I trial for Uveal melanoma in USA (Intravitreal) (NCT02771340)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top